title: Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.|CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
authors.forename: Cyrille
authors.initials: C
authors.lastname: Touzeau
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.|CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
authors.forename: Steven
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.
authors.forename: Béatrice
authors.initials: B
authors.lastname: Mahé
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.
authors.forename: Jean Samuel
authors.initials: JS
authors.lastname: Boudreault
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Gastinne
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Blin
authors.affiliation: Biochemistry Laboratory, University Hospital, Nantes, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Caillon
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.|CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
authors.forename: Christelle
authors.initials: C
authors.lastname: Dousset
authors.affiliation: Department of Hematology, University Hospital, Nantes, France.|CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Amiot
authors.affiliation: Department of Hematology, University Hospital, Nantes, France philippe.moreau@chu-nantes.fr.|CRCNA, INSERM, CNRS, University of Nantes, Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D016923:Cell Death / Q000187:drug effects; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11; D002883:Chromosomes, Human, Pair 14; D002886:Chromosomes, Human, Pair 17; D057176:Compassionate Use Trials; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use*; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D013449:Sulfonamides; C579720:venetoclax